Achieve Life Sciences (Achieve Life Sciences) Interest Coverage : 0 (At Loss) (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Achieve Life Sciences Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Achieve Life Sciences's Operating Income for the three months ended in Dec. 2023 was $-4.39 Mil. Achieve Life Sciences's Interest Expense for the three months ended in Dec. 2023 was $-0.79 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Achieve Life Sciences's Interest Coverage or its related term are showing as below:

ACHV's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 142.97
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Achieve Life Sciences Interest Coverage Historical Data

The historical data trend for Achieve Life Sciences's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Achieve Life Sciences Interest Coverage Chart

Achieve Life Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Coverage

Get a 7-Day Free Trial

N/A

Achieve Life Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Coverage	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Achieve Life Sciences's Interest Coverage

For the Biotechnology subindustry, Achieve Life Sciences's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Achieve Life Sciences's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achieve Life Sciences's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Achieve Life Sciences's Interest Coverage falls into.

Achieve Life Sciences Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Achieve Life Sciences's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Achieve Life Sciences's Interest Expense was $-2.85 Mil. Its Operating Income was $-27.25 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.01 Mil.

Achieve Life Sciences did not have earnings to cover the interest expense.

Achieve Life Sciences's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Achieve Life Sciences's Interest Expense was $-0.79 Mil. Its Operating Income was $-4.39 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.01 Mil.

Achieve Life Sciences did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's Financial Strength is.

Achieve Life Sciences (NAS:ACHV) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Achieve Life Sciences Interest Coverage Related Terms

Thank you for viewing the detailed overview of Achieve Life Sciences's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Achieve Life Sciences (Achieve Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achieve Life Sciences Inc (NAS:ACHV) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

SP4P:Germany

Address

22722 29th Dr. SE, Suite 1000, Bothell, WA, USA, 98021

Website

https://www.achievelifesciences.com

Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for nicotine addiction.

Executives

John Bencich	officer: CFO and PFO	2401 FOURTH AVENUE, SUITE 1050, SEATTLE WA 98121
Stuart Duty	director	22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Thomas Sellig	director	22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Thomas Braxton King	director	91 JAMES AVENUE, ATHERTON CA 94027
Dialectic Life Sciences Spv Llc	10 percent owner	C/O DIALECTIC LS MANAGER LLC, 119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
Dialectic Ls Manager Llc	10 percent owner	119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
John Fichthorn	10 percent owner	C/O DIALECTIC CAPITAL MANAGEMENT, LLC, 17 STATE STREET, SUITE 3930, NEW YORK NY 10004
Dialectic Capital Management, Lp	10 percent owner	119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
Dialectic Partners, Llc	10 percent owner	2ND FLOOR 119 ROWAYTON AVE, NORWALK CT 06853
Vaughn B Himes	director	C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021
Financial Group Svb	10 percent owner	2270 SAND HILL ROAD, MENLO PARK CA 94025
Svb Innovation Credit Partners Viii, Llc	10 percent owner	2770 SAND HILL ROAD, MENLO CITY CA 94025
Svb Innovation Credit Fund Viii, L.p.	10 percent owner	C/O SVB INNOVATION CREDIT PARTNERS VIII, 2770 SAND HILL ROAD, MENLO PARK CA 94025
Innovation Credit Fund Viii-a, L.p.	10 percent owner	2770 SAND HILL ROAD, MENLO PARK CA 94025
Svb Innovation Credit Partners Viii-a, Llc	10 percent owner	2770 SAND HILL ROAD, MENLO CITY CA 94025